Vaxil tested Immucin in combination with other immunotherapy modalities including checkpoint inhibitors PD1 and CTLA4.
PD-1 is a checkpoint protein on immune cells, called T cells, that stops them from from attacking other cells in the body, but some cancerous cells also have large amounts of PD-1 and can trick the body into leaving them alone.
New immunotherapy treatments such as Immucin are designed to help the immune system recognise these cancerous cells and destroy them.
There was also good progress in the use of Immucin as a neo-antigen, with potential to strongly stimulate the immune system, Vaxil said.
Neo-antigens are mutated proteins found only on the surface of cancer cells and have been shown to elicit a specific immune response against the tumor.
If Immucin can be provoke a robust immune response in cancer patients it can be targeted to bind itself to cancerous cells.
Dr Chen, Vaxil’s VP of Operation, said new data was building in support Immucin acting as a neo-antigen, while as a combination therapy the drug had several key advantages that could make it an optimal candidate to use alongside another drug.
The drug has already received Orphan Drug Designation in the US and Europe and completed a successful Phase-I/II trial.
Story by ProactiveInvestors